Bimagrumab
Bimagrumab (BYM338) is a human monoclonal antibody developed by Novartis to treat pathological muscle loss and weakness. On August 20, 2013 it was announced that bimagrumab was granted breakthrough therapy designation for sporadic inclusion body myositis (sIBM) by US Food and Drug Administration. Bimagrumab is currently entering Phase II development, with some research indicating clinical effects. In 2016, Novartis intends to apply for FDA approval to treat sIBM patients with Bimagrumab BYM338.
primaryTopic
Bimagrumab
Bimagrumab (BYM338) is a human monoclonal antibody developed by Novartis to treat pathological muscle loss and weakness. On August 20, 2013 it was announced that bimagrumab was granted breakthrough therapy designation for sporadic inclusion body myositis (sIBM) by US Food and Drug Administration. Bimagrumab is currently entering Phase II development, with some research indicating clinical effects. In 2016, Novartis intends to apply for FDA approval to treat sIBM patients with Bimagrumab BYM338.
has abstract
Bimagrumab (BYM338) is a human ...... tients with Bimagrumab BYM338.
@en
ATC prefix
CAS number
1356922-05-8
Wikipage page ID
40,294,938
Wikipage revision ID
729,904,577
ChemSpiderID
molecular weight
target
hypernym
comment
Bimagrumab (BYM338) is a human ...... tients with Bimagrumab BYM338.
@en
label
Bimagrumab
@en